"Hypercholesterolemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Descriptor ID |
D006937
|
| MeSH Number(s) |
C18.452.584.500.500.396
|
| Concept/Terms |
Hypercholesterolemia- Hypercholesterolemia
- Hypercholesterolemias
- High Cholesterol Levels
- Cholesterol Level, High
- Cholesterol Levels, High
- High Cholesterol Level
- Level, High Cholesterol
- Levels, High Cholesterol
- Elevated Cholesterol
- Cholesterol, Elevated
- Cholesterols, Elevated
- Elevated Cholesterols
- Hypercholesteremia
- Hypercholesteremias
|
Below are MeSH descriptors whose meaning is more general than "Hypercholesterolemia".
Below are MeSH descriptors whose meaning is more specific than "Hypercholesterolemia".
This graph shows the total number of publications written about "Hypercholesterolemia" by people in this website by year, and whether "Hypercholesterolemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2008 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypercholesterolemia" by people in Profiles.
-
Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ, Kosciuk MC, Nagele EP, Demarshall C, Freeman T, Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele RG. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013; 35(1):179-98.
-
Gragnoli C. Hypercholesterolemia and a candidate gene within the 12q24 locus. Cardiovasc Diabetol. 2011; 10:38.
-
Liu HR, Tao L, Gao E, Qu Y, Lau WB, Lopez BL, Christopher TA, Koch W, Yue TL, Ma XL. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res. 2009 Feb 1; 81(2):344-52.
-
van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008 Jun; 22(6):483-8.
-
Rincon F, Sacco RL. Secondary stroke prevention. J Cardiovasc Nurs. 2008 Jan-Feb; 23(1):34-41; quiz 42-3.
-
Foley KA, Denke MA, Kamal-Bahl S, Simpson R, Berra K, Sajjan S, Alexander CM. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006 May; 44(5):421-8.
-
Duffy D, Rader DJ. High-density lipoprotein cholesterol therapies: the next frontier in lipid management. J Cardiopulm Rehabil. 2006 Jan-Feb; 26(1):1-8.
-
Cheng C, Graziani C, Diamond JJ. Cholesterol-lowering effect of the Food for Heart Nutrition Education Program. J Am Diet Assoc. 2004 Dec; 104(12):1868-72.
-
Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004 Apr 1; 62(1):135-44.
-
Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation. 2003 Dec 2; 108(22):2805-11.